ArticleMolecular medicine reports2021
Protective effect of carvacrol on liver injury in type 2 diabetic db/db mice.
Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- The Effect ofFood science & nutrition · 2026Article
- Hepatoprotective effects of carvacrol: molecular mechanisms and insights from pre-clinical Studies.Molecular biology reports · 2026Review
- Carvacrol from Moringa oleifera as a potential antidiabetic agent using integrated in-silico approach inhibiting TCF7L2.Scientific reports · 2026Article
- Carvacrol attenuated acute renal injury induced by unilateral ureteral obstruction in male rats.Iranian journal of basic medical sciences · 2026Article
- Unlocking the potential ofFrontiers in nutrition · 2026Article
- Article
- Car@PLGA-NPs target gut microbiota-ER stress axis to combat diabetes.Frontiers in cellular and infection microbiology · 2025Article
- Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration.Frontiers in pharmacology · 2025Article
- Role of toll-like receptor 4/mutant myeloid differentiation primary response 88/nuclear factor kappa-B mediated inflammation in diabetes mellitus with Northwest dryness syndrome.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Article
- Oregano Essential Oil in Livestock and Veterinary Medicine.Animals : an open access journal from MDPI · 2024Review
- Sex differences in diabetes‑induced hepatic and renal damage.Experimental and therapeutic medicine · 2024Article
- Carvacrol improves blood lipid and glucose in rats with type 2 diabetes mellitus by regulating short-chain fatty acids and the GPR41/43 pathway.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2024Article
- Validating the Health Benefits of Coffee Berry Pulp Extracts in Mice with High-Fat Diet-Induced Obesity and Diabetes.Antioxidants (Basel, Switzerland) · 2023Article
- Screening of Potential ProbioticPolish journal of microbiology · 2023Article
- Effect and Correlation ofFoods (Basel, Switzerland) · 2023Article
- Hypoglycemic and HFrontiers in nutrition · 2023Article
- Use of Monoterpenes as Potential Therapeutics in Diabetes Mellitus: A Prospective Review.Advances in pharmacological and pharmaceutical sciences · 2023Review
- Ileum transcriptional response to prolonged supplementation with phytogenic product containing menthol, carvacrol and carvone.Heliyon · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the protective effect of carvacrol on liver injury in mice with type 2 diabetes mellitus (T2DM) and to assess its potential molecular mechanism. Mice were divided into three groups (n=15/group): Non‑diabetic db/m+ mice group, db/db mice group and db/db mice + carvacrol group. In the db/db mice + carvacrol group, db/db mice were administered 10 mg/kg carvacrol daily by gavage for 6 weeks. Fasting blood glucose and insulin levels were separately examined. Pathological changes were observed using hematoxylin and eosin, Masson's trichrome, periodic acid Schiff and reticular fiber staining. In addition, immunohistochemistry, immunofluorescence and western blotting were used to examine the expression levels of Toll‑like receptor 4 (TLR4), NF‑κB, NALP3, AKT1, phosphorylated (p)‑AKT1, insulin receptor (INSR), p‑INSR, mTOR, p‑mTOR, insulin receptor substrate 1 (IRS1) and p‑IRS1 in the liver tissues. The results revealed that carvacrol improved blood glucose and insulin resistance of T2DM db/db mice. After treatment with carvacrol for 6 weeks, the serum levels of TC, TG and LDL‑C were markedly reduced, whereas HDL‑C levels were significantly increased in db/db mice. Furthermore, carvacrol administration significantly decreased serum ALT and AST levels in db/db mice. Serum BUN, Cre and UA levels were markedly higher in db/db mice compared with those in the control group; however, carvacrol treatment markedly reduced their serum levels in db/db mice. Furthermore, histological examinations confirmed that carvacrol could protect the liver of db/db mice. Carvacrol could ameliorate liver injury induced by T2DM via mediating insulin, TLR4/NF‑κB and AKT1/mTOR signaling pathways. The present findings suggested that carvacrol exerted protective effects on the liver in T2DM db/db mice, which could be related to insulin, TLR4/NF‑κB and AKT1/mTOR signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.